dc.creatorMuscará, M N
dc.creatorPedrazzoli, J
dc.creatorMiranda, E L
dc.creatorFerraz, J G
dc.creatorHofstätter, E
dc.creatorLeite, G
dc.creatorMagalhães, A F
dc.creatorLeonardi, S
dc.creatorDe Nucci, G
dc.date1995-Nov
dc.date2015-11-27T12:18:39Z
dc.date2015-11-27T12:18:39Z
dc.date.accessioned2018-03-29T00:51:38Z
dc.date.available2018-03-29T00:51:38Z
dc.identifierBritish Journal Of Clinical Pharmacology. v. 40, n. 5, p. 477-80, 1995-Nov.
dc.identifier0306-5251
dc.identifier
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/8703652
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/193873
dc.identifier8703652
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1294106
dc.descriptionMetronidazole pharmacokinetics were studied in patients with different degrees of liver cirrhosis, classified according to the Child-Pugh algorithm (A, B or C, as liver disease severity increases) and in schistosomic patients. Metronidazole (500 mg) was administered i.v. as a slow infusion over 20 min, and blood samples were collected at set intervals after the end of the infusion. The plasma concentrations of metronidazole and its main metabolite hydroxy-metronidazole were quantified by reversed-phase h.p.l.c. with u.v. detection. The metronidazole and hydroxy-metronidazole areas under the curve from 0 to 24 h (AUC0,24h), the metronidazole terminal elimination half-life (t1/2), the total clearance (CL), the metronidazole volume of distribution (V) values and the hydroxy-metronidazole/metronidazole concentration ratios as a function of time were calculated for each group. Comparison of the metronidazole AUC0,24h, t1/2 and CL values revealed that metronidazole metabolism is progressively impaired as the severity of liver disease increases. There were no variations in these parameters between the schistosomic and Child-Pugh A groups. In addition, there were no differences in the V and hydroxy-metronidazole AUC0,24h among the various groups studied. However, metronidazole metabolism was delayed in patients with hepatic disease, as illustrated by the hydroxy-metronidazole/metronidazole ratio 10 min after the end of metronidazole infusion. These results indicate that the clinical assessment of liver disease is paralleled by an impairment of metronidazole metabolism. Of the studied variables, we propose the hydroxy-metronidazole/metronidazole ratio 10 min after metronidazole infusion as a suitable and practical index for liver function evaluation.
dc.description40
dc.description477-80
dc.languageeng
dc.relationBritish Journal Of Clinical Pharmacology
dc.relationBr J Clin Pharmacol
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAdult
dc.subjectBiotransformation
dc.subjectFemale
dc.subjectHalf-life
dc.subjectHumans
dc.subjectLiver Cirrhosis
dc.subjectLiver Function Tests
dc.subjectMale
dc.subjectMetronidazole
dc.subjectMiddle Aged
dc.subjectSchistosomiasis Mansoni
dc.titlePlasma Hydroxy-metronidazole/metronidazole Ratio In Patients With Liver Disease And In Healthy Volunteers.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución